Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 14/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21881185 | 1.00 | AGTR2 (0.59) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL21881848 | 1.00 | AGTR2 (0.59) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL29758892 | 0.99 | AGTR2 (0.58) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL21596260 | 0.99 | AGTR2 (0.58) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL23315467 | 0.91 | AGTR2 (0.49) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL21881614 | 0.91 | AGTR2 (0.49) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL21602377 | 0.91 | AGTR2 (0.52) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL21881389 | 0.90 | AGTR2 (0.51) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL21881186 | 0.90 | AGTR2 (0.49) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL21881194 | 0.90 | AGTR2 (0.49) | AGTR2AGTR1KDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384097-B2 | Tetrahydroisoquinoline derivative, preparation method therefor and use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-20210277021-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2021-09-09 | — | — | US | disclosed |
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-06-01 | — | — | US | disclosed |
| EP-3819293-A1 | ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2021-05-12 | — | — | EP | disclosed |
| EP-3620454-B1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| CN-106478502-B | 1,2,3, 4-tetrahydroisoquinoline derivatives, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-107922340-B | 1,2,3, 4-tetrahydroisoquinoline derivatives, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-02 | — | — | US | disclosed |
| WO-2019242599-A1 | TETRAHYDRO ISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2019-12-26 | — | — | WO | disclosed |
| WO-2017036318-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384097-B2 | Tetrahydroisoquinoline derivative, preparation method therefor and use thereof | AGTR2, AGTR1, AVPR2 | AGTR2 1/4885AGTR1 2/4885KDM4E 3999/4885 |
| US-20200102275-A1 | CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST | AGTR2, AGTR1, HCAR2 | AGTR2 1/4885AGTR1 2/4885KDM4E 4199/4885 |
| US-11021445-B2 | Carboxylic acid derivative as AT2R receptor antagonist | AGTR2, AGTR1, HCAR2 | AGTR2 1/4885AGTR1 2/4885KDM4E 4199/4885 |
| US-20210277021-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | AGTR2, AGTR1, AVPR2 | AGTR2 1/4885AGTR1 2/4885KDM4E 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.